MBIO vs. ABVC, VAXX, AEZS, OGEN, CMMB, ATHE, NCNA, KTRA, CANF, and UPC
Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include ABVC BioPharma (ABVC), Vaxxinity (VAXX), Aeterna Zentaris (AEZS), Oragenics (OGEN), Chemomab Therapeutics (CMMB), Alterity Therapeutics (ATHE), NuCana (NCNA), Kintara Therapeutics (KTRA), Can-Fite BioPharma (CANF), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical preparations" industry.
ABVC BioPharma (NASDAQ:ABVC) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.
Mustang Bio received 169 more outperform votes than ABVC BioPharma when rated by MarketBeat users.
In the previous week, ABVC BioPharma had 1 more articles in the media than Mustang Bio. MarketBeat recorded 3 mentions for ABVC BioPharma and 2 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 0.57 beat ABVC BioPharma's score of 0.44 indicating that ABVC BioPharma is being referred to more favorably in the media.
Mustang Bio has a consensus price target of $12.00, indicating a potential upside of 5,864.21%. Given ABVC BioPharma's higher possible upside, analysts plainly believe Mustang Bio is more favorable than ABVC BioPharma.
ABVC BioPharma has higher revenue and earnings than Mustang Bio. ABVC BioPharma is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.
ABVC BioPharma has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.
11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 11.9% of ABVC BioPharma shares are held by insiders. Comparatively, 2.1% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Mustang Bio has a net margin of 0.00% compared to Mustang Bio's net margin of -50,504.00%. Mustang Bio's return on equity of -207.72% beat ABVC BioPharma's return on equity.
Summary
ABVC BioPharma beats Mustang Bio on 9 of the 15 factors compared between the two stocks.
Get Mustang Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mustang Bio Competitors List
Related Companies and Tools
